drugset / Trial / NCT00556140

The Combination of Aripiprazole and Antidepressants in Psychotic Major Depression

NCT00556140

NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to assess the safety and effectiveness of the combination of aripiprazole (Abilify) and selective serotonin reuptake inhibitors (SSRIs) in subjects with psychotic major depression.

Timeline

Start
2003-06
Primary completion
2008-01
Completion
2008-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Aripiprazole Other / unclassified 10 mg

Indications